Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Atopic Eczema (US)

Articles with lock require a subscription to GLG News | Request a free trial
June 5, 2007
Melafind
Analysis of: Digital Diagnosis: New Tool for Detecting Skin Cancer | www.ehponline.org
Author: GLG Expert Contributor
Depending on the accuracy and cost of the technology, this device could be a useful and welcome tool in melanoma diagnosis.  To be considered useful, the Melafind device must increase melanoma recognition without a significant false negative rate.  In other words, the machines ability to catch...
Sunil DhawanJune 4, 2007
Melafind Phase three implications
Analysis of: Digital Diagnosis: New Tool for Detecting Skin Cancer | www.ehponline.org
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
If Melafinds phase three study results are positive then physicians will in general be receptive. The only issues are: 1. Ease of use/time to scan 2. Ability for non physician personnel to be trained to use the technology. 3. cost 4. Insurance reimbursement The technology may have more use at larger...
Sunil DhawanJune 4, 2007
Modus product-?efficacy
Analysis of: No Hydroquinone, Means No Worries for Modus. Dr.’s Applaud Europe’s New Import To Fight Signs of Aging | www.rushprnews.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The new Modus product "without hydroquinone" cannot be fully evaluated on the basis of the currently available information. Decisions based on the opinions of a "Beauty Editor", and 6 years worth of studies with only 4 patients, are tenuous at best, and laughable at worst. It will be difficult to unseat...
May 31, 2007
This drug has little advantage of existing drugs and will be difficult to get insurance approvals
Analysis of: FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets For The Relief Of Seasonal And Year Round Allergies, And Chronic Hives | www.medicalnewstoday.com
Author: GLG Expert Contributor
Yet another antihistamine in a saturated market with less expensive alternatives. Antihistamines are not the drug of choice for significant allergic rhinitis
May 29, 2007
New Organiceuticals May Help Bring Back Beauty!
Analysis of: http://www.nytimes.com/2007/04/26/fashion/26skin.html?_r=1&ref=health&oref=slogin | www.nytimes.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
All that glitters is not gold...but some might be! Anti-oxidants are the promise of saving our "hides"!
May 28, 2007
Couldn't agree more
Analysis of: FDA May Place Ban on OTC Bleaching Creams | www.carefair.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Keep Hydroquinones Around!
Sunil DhawanMay 24, 2007
FDA Hydroquinone ban may be premature
Analysis of: FDA May Place Ban on OTC Bleaching Creams | www.carefair.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The possible ban of over the counter hydroquinone skin bleaching agents may be premature. We have used these agents for 20 years without any significant side effects including ochronosis or paradoxical darkening of the skin. These agents are only modestly effective at best. Most patients still...
May 17, 2007
Non-Invasive Screening of the Skin
Analysis of: New tool allows noninvasive screening of skin lesions | www.modernmedicine.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
The company hopes to apply for European regulatory approval next year, with U.S. market approval and launch to follow. The current price of the device is 15,000 EUR. This device promises to be a remarkable time and money saver for medicine. Approximately 80-95% of lesions excised by dermatologists prove...
May 17, 2007
Pulsed Dye Vs Excimer Laser for Psoriasis
Analysis of: Psoriasis Challenge: pulsed dye vs. excimer lasers | www.modernmedicine.com
Author: Kenneth Edelson, Owner, Kenneth Edelson, MD
Patient satisfaction is high, but long term effects including possible carcinogenesis remain uncertain. Side effects included blistering, and hyperpigmentation in both groups, but no scarring.
Sunil DhawanMay 4, 2007
Ceragenix Epiceram product phase 4 results positive
Analysis of: Ceragenix Announces Results from Phase IV Study of EpiCeram(TM) Meet All Primary and Secondary Endpoints | www.irconnect.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recent Epiceram phase 4 data comparing it to Cutivate are positive, and bode well for the product. The concept of barrier repair makes sense in light of the recent findings in regards to the genetic basis of atopic dermatitis. Repairing the barrier with Epiceram will reduce inflammation, and the...

Previous Page : 1 2 3 4 5 6 7 8 Next51 to 60 of 80

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203